Knoa Pharma
As of the edition of 20 October 2026, Knoa Pharma runs 7 drugs, 6 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 1 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Morphine | none listed | 2 |
| Buprenorphine | Ends 2028 (exclusivity) | 9 |
| Methylphenidate | none listed | 11 |
| Oxycodone | none listed | 2 |
| Hydrocodone | none listed | 9 |
| Nalmefene | none listed | 9 |
A route B row is one company at one target.
Where its trials are
- Chemically induced: 2 trials led
- Mental health: 2 trials led